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 Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract 
disease and bronchiolitis in children worldwide. No vaccine or specific, effective treatment 
is currently available. β-escin is one of the main bioactive constituents of Aesculus 
hippocastanum L. (Hippocastanaceae) seed extract (AH), and both β-escin and AH have 
demonstrated a beneficial role in clinical therapy because of their anti-edematous, anti-
inflammatory and antioxidative effects. Besides, we have reported that β-escin and AH 
show virucidal, antiviral and immunomodulatory activities against the enveloped viruses 
HSV-1, VSV and Dengue virus in vitro. In this study, we demonstrate that β-escin and AH 
have virucidal and antiviral activities against RSV, as well as NF-κB, AP-1 and cytokine 
modulating activities in RSV infected epithelial and macrophage cell lines in vitro. Besides, 
in a murine model of pulmonary RSV infection, AH treatment improves the course of acute 
disease, evidenced by decreased weight loss, reduced RSV lung titers, and attenuated 
airway inflammation. In contrast, even though β-escin showed, similarly to AH, antiviral 
and immunomodulatory properties in vitro, it neither reduces viral titers nor attenuates lung 
injury in vivo. Thus, our data demonstrate that AH restrains RSV disease through antiviral 
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 The human respiratory syncytial virus (RSV) infection is a leading cause of acute 
respiratory tract infections in early childhood (Hall et al, 2013). The infection is frequently 
associated with bronchiolitis and pneumonia. RSV bronchiolitis is potentially life-
threatening and requires admission to hospital (Piedimonte and Perez, 2014). Moreover, 
children experiencing severe or recurrent bronchiolitis have an increased risk for recurrent 
wheeze and asthma (Sigurs et al, 2010; Krishnamoorthy et al, 2012).  The World Health 
Organization estimated that RSV is responsible for over 33 million new episodes of acute 
lower respiratory infection in children younger than 5 years (Nair et al, 2010).  RSV causes 
significant mortality in the developing world, resulting in an estimated 200,000 annual 
deaths in young children globally, in addition to major morbidity (33.8 million episodes 
worldwide annually) (Nair et al, 2010). Besides, RSV is a leading cause of morbidity and 
mortality in elderly and immunocompromised individuals (Kwon et al, 2017). 
 The transmission of RSV is difficult to prevent since it is easily transmitted by close 
contact and by unprotected coughing and sneezing. Although practically all children will 
have had an infection by the age of two (Dawson-Caswell and Muncie et al 2011), 
recurrent infection is very common since the virus has developed an arsenal of strategies 
to modulate host immune response and antiviral immunity (Christiaansen et al 2015; 
Larranaga et al 2009). The virus has the ability to modulate cytokine and chemokine 
signalling networks, such as NF-κB and AP-1 signalling pathways, interfere with immune 
cell function and antibody response (Dey et al, 2011; Christiaansen et al 2015; Li et al, 
2016). Despite the prevalence of RSV bronchiolitis, there is no vaccine available and, 
apart from supportive measures, there is no specific effective treatment (Tregoning and 
Schwarze, 2010) since routine use of bronchodilators or antiviral ribavirin has been proven 













In the last years, plant extracts and herbal compounds have been investigated for 
their antiviral and immunomodulatory properties (Hassan et al. 2015: Bueno et al, 2015; 
Michelini et al, 2018; Shi et al, 2016). β-escin is one of the main bioactive constituents of 
Aesculus hippocastanum L. (Hippocastanaceae) seed extract (AH), and both β-escin and 
AH have demonstrated a beneficial role in clinical therapy because of their anti-
edematous, anti-inflammatory and antioxidative effects (Sirtori, 2001; Pittler and Ernst. 
2012).  In fact, in the United States and Europe, they are one of the best-selling herbal 
products (Domanski et al. 2016). With respect to their mechanism of action, we and others 
have reported that β-escin and AH modulate NF-κB and AP-1 activation in different cell 
types and conditions in vitro (Cheng et al. 2015; Domanski et al. 2016; Liu et al. 2012; 
Michelini et al, 2018). Moreover, we have demonstrated virucidal and broad spectrum 
antiviral activities for β-escin and AH against the enveloped viruses HSV-1, VSV and 
Dengue (Michelini et al, 2018). 
Thus, considering that NF-κB and AP-1 activation play an important role in RSV 
replication (Dey et al, 2011; Li et al, 2016), the aim of the present study was to examine 
the antiviral activity of β-escin and AH against RSV in epithelial cells, as well as their effect 
on the activation of the NF-κB and AP-1 signalling pathways and on the production of 
different cytokines in RSV infected epithelial and macrophage cell lines. Finally, we studied 
their activity against RSV infection in a murine model of pulmonary infection.  
 
2. Materials and Methods 
 
2.1 Herbal extract and chemical compound 
β-escin and AH used in the experiments were obtained as a lyophilized powder in a 













Aires, Argentina. β-escin was originally obtained from Indena S.p.A., Milan, Italy (Batch N° 
31259/M2) with a purity of 98.3%, as stated by the manufacturer. The identification and 
purity were also analyzed by Spedrog Callion S.A. by HPLC, and complies the 
specifications of the Argentinian Pharmacopoeia. AH was originally purchased from Martin 
Bauer Group (Finzelberg GmbH & Co), Andernach, Germany (Batch N° 13013823). This 
herbal extract was produced according to the German Pharmacopoeia (Deutsches 
Arzneibuch – DAB). AH contains about 3-6% of escin (according to DAB, not less than 
3%, expressed as anhydrous escin and calculated with reference to the dried drug). 
Moreover, the identity (Thin-layer Chromatography (TLC)) and purity (High performance 
liquid chromatography (HPLC)) were also analyzed by Spedrog Callion S.A., and complies 
the specifications of the Argentinian Pharmacopoeia. 
The β-escin and AH used in this report were approved by Food, Drug and Medical 
technology Administration (ANMAT) in Argentina to be administered in humans. 
AH was dissolved in DMEM/F12, and β-escin was dissolved in dimethylsulfoxide 
(DMSO) and diluted with DMEM/F12. The maximum concentration of DMSO used (1%) 
exhibited no toxicity under in vitro and in vivo conditions. 
 
2.2 Cells and viruses 
The human HEp-2 cell line (human epidermoid cancer cell line) and the human 
A549 cell line (human lung carcinoma cell line) were grown in DMEM/F12 supplemented 
with 10% inactivated fetal bovine serum (FBS) (DMEM/F12, 10%), Murine macrophage 
cell line J774A.1 was kindly provided by Dr. Osvaldo Zabal (INTA–Castelar, Buenos Aires, 
Argentina) and grown in RPMI 1640 medium supplemented with 10% FBS. Vero cells 
were grown in MEM supplemented with 10% FBS. Human RSV strains A2 and line 19 
were kindly provided by Dr. Laura Talarico (INFANT–Buenos Aires, Argentina). Working 













semiconfluent monolayers of HEp-2 cells were infected with RSV strains line 19 and A2 
(multiplicity of infection (moi)=0.2) and were incubated 3–4 days, monitoring the 
development of CPE daily, until CPE ≥80% of cell monolayer, but still intact and attached 
to flask bottom. Then, supernatant was removed and 5 mL of cold 25% (w/v) sterile 
sucrose was added. Then the flask was transferred to −80 °C, being sure that cell surface 
is covered with sucrose solution while in the freezer. After three cycles of freezing and 
thawing, lysates were transfered to sterile 50 mL conical tubes.  Cellular debris was 
removed by centrifugation at 500 × g and 4 °C for 1 0 min, and supernatants were 
aliquoted and stored at -80°C until use. Sucrose in  concentrations at 25% has a stabilizing 
effect and reduces loss of infectivity of this very labile virus. Virus titration was performed 
in Vero cells by plaque assay. 
 
2.3 Cytotoxicity assay 
Cell viability was determined using the tetrazolium salt MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) (Sigma) according to the manufacturer’s 
instructions.. The cytotoxic concentration 50 (CC50) was calculated as the concentration of 
compounds required to reduce cell viability by 50% relative to untreated cells, that were 
incubated with medium alone. 
 
2.4 Antiviral activity 
Cells grown in 24-well plates were infected with a moi of 1. After 1 h adsorption at 
37 °C, the inoculum was removed and medium containi ng the compounds was added, in 
triplicate. The plates were incubated at 37 °C unti l 24 h p.i. After cell disruption by freezing 
and thawing, supernatants were titrated by plaque assay in Vero cells, and the effective 













reduce viral yields by 50% relative to the untreated virus control, that were incubated with 
medium alone. 
 
2.5 Virucidal effect 
RSV line 19 and A2 (107 PFU) were diluted in culture medium containing or not 
each compound and incubated for 120 min at 37 °C. A liquots were diluted to a non-
inhibitory drug concentration and titrated by plaque assay on Vero cells. 
 
2.6 Time-of-addition assays 
For pre-infection assays, cells were treated with the compound during 2 h at 37°C, 
washed with PBS and then infected with RSV A2 (moi=1). For co-infection, cells were 
simultaneously infected with RSV A2 and treated with the compound of interest. After 1 h 
adsorption at 37°C, the virus-drug mixture was remo ved, washed and compound free 
medium was added. For post-infection (p.i.) assays, cells were infected with RSV for 1 h at 
37°C and then treated with the tested compound at 0 , 2, 4, 6, 8, 12 and 16 h after 
infection. A control culture that was infected but not treated (CV) was simultaneously 
performed. Cells were further incubated at 37 °C ti ll 24 h p.i., and after cell disruption by 
freezing and thawing, supernatants were titrated by plaque assay in Vero cells. 
 
2.7 RSV qRT-PCR assay. 
At the indicated time points p.i./compound incubation, total RNAs were extracted 
from supernatants, after freezing and thawing the infected cells, with QIAamp® Viral RNA 
Mini Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer's instructions. The 
first-strand cDNA synthesis was performed with SuperScript III Reverse Transcriptase 
(SSIII) (Thermo Fisher Scientific) following manufacturer's instructions and a primer which 













(qPCR) with primers and probe targeting the M gene previously reported (Kim et al, 2011) 
was performed with SensiFAST™ Probe No-ROX Kit (Bioline) following manufacturer's 
instructions. RNase P DNA was used as a reference gene and was amplified with the 
corresponding gene specific primers and probe and the qPCR was performed with 
SensiFAST™ Probe No-ROX Kit (Bioline). Average viral RNA Cq values were normalized 
to the average Cq values of RNase P and ∆∆Ct based fold-change calculations were set 
relative to untreated-virus infected cells at 6 h p.i. 
 
2.8 Cytokine determination 
Mouse TNF-α and IL-6, and Human IL-6 and IL-8 were quantified by commercial 




Transfection assays with Lipofectamine 2000 reagent (Invitrogen) were performed 
according to the manufacturer’s instructions. The NF-κB-LUC reporter vector and RSV-β- 
gal plasmid, coding for the bacterial β-galactosidase gene under the control of the viral 
RSV promoter, were kindly provided by Dr. Susana Silberstein (Universidad de Buenos 
Aires, Argentina). The Ap-1-LUC reporter vector was kindly provided by Prof. Dr. Thomas 
F. Schulz (Medizinische Hochschule Hannover, Germany). Reporter quantitation with 
Luciferase Assay System E1500 (Promega) was performed according to the 
manufacturer’s instructions. 
 
2.10 Pulmonary infection in mouse model.  
Animal studies were approved by the Comisión Institucional de Cuidado y Uso de 













Universidad de Buenos Aires, Argentina. Female Balb/C mice were purchased from 
Facultad de Veterinaria, Universidad de Buenos Aires, Argentina.  The animals were 
housed in an Animal Facility Biosafety Level 3 (ABSL-3) (UOCCB, ANLIS-Malbrán, 
Buenos Aires, Argentina) in individually ventilated cages and fed with food and water ad 
libitum for at least 1 week before experimental use at 6–8 week of age. Mice received 50 
µl RSV line 19 and A2 (5 × 106 PFU) or 25% (w/v) sucrose by intranasal (i.n.) delivery 
under light general anesthesia (isoflurane) (6 per group). Infectious dose was chosen 
based on references that previously characterize line 19 and A2 strains of RSV in the 
mouse model (Shi et al, 2016; Rudd et al, 2016). A total of 10 mg/kg of AH or 1 mg/kg of 
β-escin or a vehicle (control group), was given 1 h p.i. intraperitoneally (i.p.). Mice further 
received a daily dose of 10 mg/kg of AH or 1mg/kg of β-escin until day 4 p.i.  Body weights 
were monitored daily, and groups of mice were culled on day 4 or 8 p.i. Lungs from day 4 
were removed, weighed, and used for titration of infectious virus. Briefly, snap frozen lungs 
were homogenized on ice using glass Dounce homogenizers. Tissue debris was pelleted 
by centrifugation at 4°C for 10 min at 300g and sup ernatants were immediately serially 
diluted in FBS free medium and titrated by plaque assay in Vero cells. The right lungs from 
day 8 were used for gene expression studies, and in parallel, the left lung was submerged 
in Bouin solution for fixation for 24 hr and subsequent histological sectioning and staining.  
 
2.11 Cytokines qRT-PCR.  
RNA from mouse lung tissue was isolated using TRIzol reagent (Life Technologies) 
and reverse transcribed with ImProm-II™ Reverse Transcription System A3800 
(Promega), according to the manufacturer’s instructions. Quantitative PCR was performed 
on the Bio-Rad iQ5 real-time PCR system using FastStart SYBR green Master Mix 













analyzed using the 2−∆∆Ct formula. The sequences of the primers for mouse gene 
expression are listed (forward and reverse): 
TNF-α : F: CAGGCGGTGCCTATGTCTC; R: CGATCACCCCGAAGTTCAGTAG 
PrimerBank ID: 133892368c1(https://pga.mgh.harvard.edu/primerbank/) 
IL-6: F:TAGTCCTTCCTACCCCAATTTCC;  R: TTGGTCCTTAGCCACTCCTTC 
PrimerBank ID: 13624311a1 (https://pga.mgh.harvard.edu/primerbank/) 
IL-4: F: GGTCTCAACCCCCAGCTAGT; R: GCCGATGATCTCTCTCAAGTGAT 
PrimerBank ID: 10946584a1 (https://pga.mgh.harvard.edu/primerbank/) 
IFN-γ: F: ATGAACGCTACACACTGCATC; R: CCATCCTTTTGCCAGTTCCTC 
PrimerBank ID: 33468859a1(https://pga.mgh.harvard.edu/primerbank/) 
IL-17A: F: TTTAACTCCCTTGGCGCAAAA; R: CTTTCCCTCCGCATTGACAC 
PrimerBank ID: 6754324a1 (https://pga.mgh.harvard.edu/primerbank/) 
β-actin: F: GTGACGTTGACATCCGTAAAGA; R: GCCGGACTCATCGTACTCC 
PrimerBank ID 145966868c1(https://pga.mgh.harvard.edu/primerbank/) 
 
2.12 Statistical analysis 
CC50 and EC50 were calculated from dose–response curves using the software 
GraphPad Prism 4.0. Statistical significance was assessed either using a one-way analysis 
of variance (ANOVA) followed by a Tukey’s multiple comparison test, or a two-way 


















 The laboratory RSV strain A2 is important in the field as a reference strain and it 
has been used for studies including both in vitro and in vivo modeling of disease 
responses. Besides, RSV strain line 19 has been used to establish an animal model of 
severe RSV-induced disease, with significant airway hyperreactivity (AHR) and mucus 
overproduction (Woolums et al, 2011). In order to assess the antiviral activity of β-escin 
and AH against RSV, HEp-2, A549, and Vero cells were infected with both RSV strains 
line 19 and A2 (moi=1) and treated with different concentrations of β-escin and AH during 
24 h (100-0.1 µg/ml), and the selectivity index (SI), the relationship between CC50 and 
EC50 values, was calculated. β-escin and AH significantly reduced infectivity of both strains 
of RSV in a concentration-dependent manner (p<0.05) (Table 1 and 2, and Supplementary 
Figure 1). Besides, β-escin and AH have no cytotoxic effect at all concentrations tested 
(CC50>100 µg/ml).   
 Next, we evaluated whether the antiviral action against RSV was due to a direct 
inactivation of the released virus. Suspensions of RSV line 19 and A2 were incubated with 
different concentrations of β-escin and AH (100-0.1 µg/ml) for 120 min at 37°C, followed by 
titration of the remaining infectivity in Vero cells. Results showed an inactivating effect for 
β-escin and AH against both strains of RSV (Table 3 and Supplementary Figure 1).  
 These data demonstrate that β-escin and AH have virucidal and antiviral activities 
against RSV line 19 and A2 infection in vitro. 
 
 3.2 Influence of the duration of treatment with β-escin and AH on RSV infectivity 
and on RSV RNA synthesis 
To further characterize β-escin and AH inhibitory action, HEp-2 and A549 cells 
were exposed to both drugs before, during or after infection with RSV A2. Virus yields 













When β-escin (5 µg/ml) and AH (25 µg/ml) were added before or during RSV 
inoculation (moi= 1), no significant inhibition of viral multiplication was detected. However, 
RSV A2 virus yields significantly decreased when β-escin and AH were added after 
infection in HEp-2 and A549 cells (Fig 1A). 
 Then, we decided to make a time of addition assay at different times after infection. 
Results showed that β-escin (5 µg/ml) and AH (25 µg/ml) were able to inhibit infectious 
particle formation even when both were added at 8 h p.i. (Fig 1B). At later times, none of 
the compounds restrained virus infectivity in HEp-2 and A549 cells (Fig 1B). 
 Even though β-escin and AH showed virucidal properties (Table 3), they were not 
active when added during inoculation of virus particles, and, likewise, inhibition of 
infectious virus particle production is lost when these compounds were added at late times 
p.i. Besides, the concentrations of β-escin and AH needed to inactivate RSV particles were 
higher than those observed for antiviral activity. Thus, in order to analyze whether the 
dominant antiviral activity occurs intracellularly on RNA replication rather than on the virus 
particle itself, we examined if viral RNA synthesis was affected by β-escin and AH. 
Intracellular RNA synthesis of RSV A2 was analyzed by qRT-PCR at different time points 
p.i. in the presence of β-escin and AH. The amounts of viral RNA in untreated and treated 
HEp-2 cells were calculated in comparison to the content of viral RNA in untreated infected 
cells at 6 h p.i., defined as 1. As seen in Figure 1C, the time course of RSV RNA synthesis 
in control infected cells was in accordance with previous studies (Borg et al, 2003; Challa 
et al, 2015) with increasing levels of intracellular RNA from earlier to later times. At 6 h and 
12 p.i., the content of viral RNA in cells infected with RSV and treated with β-escin and AH 
was similar to that in untreated infected cells. By contrast, the relative contents of viral 
RNA in cells infected and treated with β-escin and AH decreased with time, and the 













cells was observed at 18 h and 24 h p.i., when the peak in RNA synthesis was detected for 
untreated cells (Figure 1C). These results suggested that β-escin and AH impair viral RNA 
synthesis during RSV infection. 
 
 3.3 NF-κB and AP-1 activation is modulated by β-escin and AH after RSV infection 
in epithelial and macrophage cell lines.  
NF-κB activation following RSV infection is necessary for viral replication (Masaki 
et al, 2011), and both NF-κB and AP-1 activation are required for RSV-induced cytokine 
production (Dey et al, 2011; Masaki et al, 2011; Li et al, 2016; Tian et al, 2018). Besides, 
the downregulation of NF-κB activation by β-escin has been described in different cell 
types and conditions (Cheng et al. 2015; Domanski et al. 2016; Liu et al. 2012; Michelini et 
al, 2018). Previously, we showed that β-escin and AH modulate NF-κB and AP-1 
activation in epithelial and macrophage cell lines infected with HSV-1 and stimulated with 
Toll Like Receptors (TLRs) ligands (Michelini et al, 2018). Therefore, we decided to 
investigate whether β-escin and AH could modulate RSV induced NF-κB and AP-1 
activation in epithelial and macrophage cell lines. 
 HEp-2, A549 and J774A.1 cells were transfected with a NF-κB-LUC and AP-1 
LUC reporter vector and β-galactosidase control plasmid and, 24 h later, infected with RSV 
line 19 and A2 (moi=1) and treated with β-escin (5 µg/ml) and AH (25 µg/ml) during 24 h. 
We verified that RSV line 19 and A2 induced NF-κB and AP-1 activation, and, 
interestingly, both NF-κB and AP-1 signalling pathways were strongly inhibited by β-escin 
and AH in HEp-2, A549 and J774A.1cells (Fig 2).  
 
 3.4 Modulation of cytokine production by β-escin and AH in infected epithelial and 













It has been already reported that RSV is able to activate NF-κB and AP-1 
concomitant with the expression of pro-inflammatory cytokines, including IL-6 and TNF-α 
and chemokines such as IL-8, that contribute to inflammation and the pathology of the 
infection (Dey et al, 2011; Masaki et al, 2011; Li et al, 2016). To assess the biological 
relevance of the inhibition of the activation of NF-κB and AP-1 pathways provoked by β-
escin and AH on cytokine production, we measured their effect on IL-6 and IL-8 secretion 
in infected epithelial cells, and IL-6 and TNF-α in infected macrophage cell line. 
Supernatants harvested from HEp-2, A549 and J774A.1 cells infected with RSV line 19 
and A2 strains (moi=1) and treated or not with β-escin (5 µg/ml) and AH (20 µg/ml) were 
used to quantify IL-6, IL-8 and TNF-α by ELISA.  
As expected, IL-6, IL-8 and TNF-α production were higher in RSV line 19 and A2 
infected cells than in uninfected ones (Dey et al, 2011; Masaki et al, 2011; Li et al, 2016). 
Besides, β-escin and AH significantly reduced IL-6, IL-8 and TNF-α production when 
added to RSV HEp-2, A549 and J774A.1 infected cells (Fig 3). In summary, β-escin and 
AH proved to reduce the release of IL-6, IL-8 and TNF-α in RSV-infected epithelial and 
macrophage cell lines, probably as a consequence of the inhibition of the NF-κB and AP-1 
signalling pathways. 
 
 3.5 In vivo evaluation of β-escin and AH antiviral effect 
 Having demonstrated that β-escin and AH had antiviral and immunomodulatory 
properties against RSV line 19 and A2 in vitro, the question whether these properties were 
functional in vivo was addressed. For that purpose, a well-characterized model of murine 
pulmonary RSV infection was used (Lukacs et al, 2006; Stokes et al, 2011; Rudd et al, 
2016; Woolums et al, 2011). Considering that in a mice model of allergic airway 













and lung inflammation by reducing infiltration of inflammatory cells into lung tissue and the 
release of asthma-associated cytokines, and in view of the close association between 
asthma and severe RSV infection (Lindner et al, 2010; Markus et al, 2014; Piedimont and 
Perez, 2014; Saravia et al, 2015), we decided to conduct the experiments with i.p. 
administration of β-escin and AH. In uninfected mice, an i.p. dose of 1 mg/kg of β-escin 
and 10 mg/kg of AH had no effect on general health and behavior, as previously reported 
(Sirtori et al, 2001; EMA, 2009; Pittler and Ernst, 2012). Thus, 1h after RSV line 19 and A2 
infection by nasal instillation, mice were treated with i.p. administration of either 1 mg/kg of 
β-escin or 10 mg/kg of AH. Then, mice were subsequently treated with daily administration 
with AH or β-escin until day 4 p.i. Mice injected i.p. with PBS were used as untreated 
controls. Weight loss was assessed daily, viral load was determined on days 4, and 
pulmonary gene transcription and histopathology was assessed on day 8. 
 Weight loss is a quantitative measure of RSV illness severity in the BALB/c mouse 
model (Rudd et al, 2016; Stokes et al, 2011). Line 19 and A2 RSV-infected mice treated 
with β-escin showed an early weight reduction on day 2 p.i., (Fig 4A and B), comparable to 
the weight reduction observed for untreated RSV-infected mice (Stokes et al, 2011; Rudd 
et al, 2016). In contrast, RSV line 19 and A2 infected mice treated with AH not only had 
significantly less weight loss on day 2 p.i., but also over the entire course of the 
experiment when compared to untreated infected controls (Fig 4A and B).   
 RSV line 19 and A2 titers in the lung were significantly lower in AH-treated mice 
compared to untreated animals at day 4 (the time point of peak viral load in this model) 
(Fig 4C) (Stokes et al, 2011; Rudd et al, 2016). No difference between β-escin–treated 
mice and untreated mice was observed regarding line 19 and A2 RSV titers (Fig 4C).  
 A number of cytokines have previously been outlined to be important in the severity 













to examine the magnitude of host response to infection, we evaluated cytokines gene 
expression by qPCR (Fig 5). RSV line 19 and A2 untreated and infected mice had a 
significant induction of transcript levels of pro-inflammatory cytokines TNF-α and IL-6, Th2-
type cytokine IL-4, Th1-type cytokine IFN-γ, and Th17-type cytokine IL-17A, in the lungs 
with respect to uninfected animals. Interestingly, infected mice treated with AH had 
significantly lower levels of all these cytokines than those observed in control infected 
animals. On the contrary, infected animals treated with β-escin did not show any significant 
difference compared to RSV line 19 and A2 infected mice (Fig. 5).  
  As shown in Fig. 6, RSV line 19 and A2 infection recapitulated previously reported 
abnormal histology of lung sections (Rudd et al, 2016). H&E staining showed alveolar 
walls, and alveolar spaces filled with moderate to severe inflammatory infiltrates of cells in 
infected and mock-treated group. The lung sections from AH treated group were more 
closely resembled to that of the uninfected controls. Thus, AH reduced lung inflammation 
and inflammatory cell infiltration. On the contrary, lungs sections from β-escin treated mice 
show similar histopathology injury compared to infected controls (Fig 6). 
 Taken together, these results, demonstrated that AH restrained RSV infection in 




 RSV is a leading cause of lower respiratory tract disease and bronchiolitis in 
children worldwide. Despite decades of effort, there is no a safe and efficacious RSV 
vaccine or antiviral treatment (Turner et al, 2014). Herbal medicines have demonstrated 
therapeutic efficacy for symptoms of viral infection and inflammation although the 













research provides evidence for their broad use to treat numerous diverse disorders, their 
current clinical use is restricted mainly to venotonic and venoprotective indications due to 
their anti-inflammatory and anti-edematous properties. Indeed, randomized controlled trials 
confirmed the effectiveness of β-escin and AH for the treatment of chronic venous 
insufficiency (Sirtori et al, 2001; EMA, 2009; Pittler et al. 2012).   
 Previously, we have reported that β-escin and AH show virucidal and antiviral 
activities against the enveloped viruses HSV-1, VSV and Dengue virus (Michelini et al, 
2018). In this study, we identified β-escin and AH as active herbal medicines against RSV 
in vitro. Airway epithelial cells are the major target of RSV infection in the lung, and 
importantly, β-escin and AH restrict line 19 and A2 RSV infection in epithelial cells in 
several aspects, including the inactivation of the viral particles and, more crucially, the 
inhibition of intracellular replication when added after infection. Indeed, one of the 
dominant process affected by β-escin and AH appears to be RSV RNA synthesis. 
Besides, β-escin and AH inhibit NF-κB and AP-1 signalling pathways induced by 
RSV, and consequently, they reduce pro-inflammatory cytokines production in epithelial 
and macrophage cell lines infected with RSV in vitro. Considering that NF-κB activation 
plays an important role in RSV replication (Masaki et al, 2011), the inhibition of NF-κB 
pathway in RSV-infected cells treated with β-escin and AH could account for the antiviral 
activity observed. Alternatively, the reduction of NF-κB and AP-1 activation and cytokines 
production in β-escin and AH-treated and RSV-infected cells could be due to the antiviral 
activity of these compounds. However, it is well known the downregulation of NF-κB 
activation by β-escin in different cell types and phisiopatological conditions in absence of 
infection (Cheng et al. 2015; Domanski et al. 2016; Liu et al. 2012; Michelini et al, 2018). In 
fact, it is proposed that β-escin decreases NF-κB activation as a result of perturbations in 













responses leading to cytoskeletal disarrangements, with an impact in NF-κB signal 
transduction (Domanski et al, 2016). In this sense, we have previously reported that β-
escin and AH block the activation of NF-κB and AP-1 pathways and reduce cytokine 
production in ocular epithelial cells and macrophages stimulated with non-viral stimuli, 
such as TLRs ligands (Michelini et al, 2018). In addition, we have also verified that β-escin 
and AH ablate the induction of NF-κB and AP-1 and cytokine production in HEp-2 and 
A549 cells stimulated with TLRs ligands, independently of a viral infection (Supplementary 
Figure 2). Moreover, RSV does not multiply in J774A.1 cells in our experimental settings. 
Thus, the ablation of NF-κB and AP1- induction and cytokine production upon AH and β-
escin treatment of RSV infected J774A.1 cells, could not be due to the inhibition of viral 
infection. 
 RSV activation of the NF-κB and AP-1 pathways is one of the mains factors 
involved in viral pathogenesis in vivo (Li et al, 2016; Tian et al, 2018).  The host senses 
RSV invasion through pattern recognition receptors, leading to the activation of NF-κB and 
AP-1 signalling pathways, increased cytokine production, inflammatory cell influx, and 
subsequently mucus production, AHR and reduced lung function (Li et al, 2016; Tian et al, 
2018). Thus, blockade of these signalling pathways involved in immunopathology during 
RSV infections may be an effective therapeutic strategy with a low risk of emergence of 
viral resistance. In this paper, in mice infected with RSV line 19 and A2 and treated with 
AH, there was not only a reduction of the viral titers, but also a reduction of the lung injury. 
In addition, there was a significant decrease in cytokine gene expression in AH treated 
infected mice, consistent with results from histological studies.  Thus, considering that AH 
blocked NF-κB and AP-1 signalling pathways in vitro and its well known 
immunomodulatory activity in different in vivo models (Cheng et al. 2015; Domanski et al. 













against pulmonary RSV infection not only by blocking viral infection processes but also by 
modulating the immune response. 
 In contrast, even though β-escin showed, similarly to AH, antiviral and 
immunomodulatory properties in vitro, it neither reduces viral titers nor attenuates lung 
injury in vivo, in the dose and route of administration tested. Since β-escin is one of the 
main constituent of AH together with others (AH contains 3-6% of escin), and that the dose 
of 10 mg/kg of AH contains less than 1 mg/kg of β-escin, the antiviral and 
immunomodulatory effects observed in AH treated infected mice would be ascribed to a 
synergic effect of some components present in the extract. In fact, it is reported that the 
therapeutically active constituent in AH is not known with certainty, and that the data in 
support of β-escin as the active substance of AH in chronic venous insufficiency is very 
weak (EMA, 2009). 
 
  Conclusion 
 This study demonstrates that β-escin and AH have virucidal and antiviral activities 
against RSV, as well as NF-κB, AP-1 and cytokine modulating activities in RSV infected 
cells in vitro. Besides, in an in vivo model of RSV, AH treatment improves the course of 
acute disease, evidenced by decreased weight loss, reduced RSV lung titers, and 
attenuated airway inflammation. Thus, our data demonstrate that AH restrains RSV 
disease through antiviral and immunomodulatory effect. In this paper, we have shown that 
AH is highly effective if applied by i.p.administration. In view of a clinical application in 
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Table 1. EC50 of β-escin and AH against RSV line 19 and A2 
Compound EC50 (µg/ml)  
HEp-2 A549 Vero 
line 19 A2 line 19 A2 line 19 A2 
β-escin 1.6 ± 0.3 1.4 ± 0.7 2.4 ± 0.8 1.8 ± 0.2 1.5 ± 0.5 2 .6 ± 0.23 
AH 13.3 ± 0.4 12.7 ± 1.2 14 ± 1.2 17 ± 3.4 7.5 ± 0.6 9.8 ± 2.7 
 
EC50: Effective Concentration 50. EC50 were calculated by nonlinear regression. Data 
represent mean ± SD for n = 3 independent experiments, performed in triplicate. 




Table 2. SI of β-escin and AH against RSV line 19 and A2 
 
Compound SI (CC50/CE50) 
HEp-2 A549 Vero 
line 19 A2 line 19 A2 line 19 A2 
β-escin 62.5 71.4 41.6 55.5 66.7 38.4 
AH 7.5 7.9 7.1 5.9 13.3 10.2 
 
SI: selectivity indices (ratio CC50/CE50) 
















Table 3. Virucidal activity of β-escin and AH against RSV line 19 and A2 
 
Compound EC50 (µg/ml) 
 line 19 A2 
β-escin 14.5 ± 2.3 15.1 ± 3.1 
AH 68.5 ± 5.8 65.9 ± 8.7 
 
EC50: Effective Concentration 50. EC50 were calculated by nonlinear regression. Data 
represent mean ± SD for n = 3 independent experiments, performed in triplicate. 





Figure 1. Influence of time of treatment with β-escin and AH on RSV infectivity and 
on RSV RNA synthesis. (A) For pre-infection assays, HEp-2 and A549 cells were 
exposed or not to β-escin (5 µg/ml) and AH (25 µg/ml) during 2 h, washed with PBS, and 
then infected with RSV A2 (moi=1) during 24 h. For co-infection, cells were simultaneously 
infected with RSV A2 (moi=1) and treated with the compound of interest. After 1 h 
adsorption, the virus-drug mixture was removed, washed with PBS, and compound free 
medium was added during 24 h. For p.i. assays, cells were infected with RSV A2 (moi=1) 
for 1 h, and then treated with the tested compound for 24 h. (B) HEp-2 and A549 cells 
infected with RSV A2 (moi=1) were treated or not (control) with β-escin (5 µg/ml) and AH 













assay in Vero cells at 24 h p.i and plotted as the percentage of inhibition with respect to 
untreated–infected control (CV). (C) HEp-2 cells were infected with RSV A2 (moi=1) and 
treated or not (control) with β-escin (5 µg/ml) and AH (25 µg/ml). Total cellular RNA was 
extracted at the indicated times p.i. and viral RNA was quantified by qRT-PCR. The 
amounts of viral RNA in untreated and treated HEp-2 cells were calculated in comparison 
to the content of viral RNA in untreated infected cells at 6 h p.i., defined as 1. Data 
represent mean ± SD for n = 3 independent experiments, performed in duplicate. 
*Significantly different from CV (p-value <0.05). 
 
Figure 2.  Effect of β-escin and AH on NF-κB and AP-1 activation in RSV infected 
cells.  J774A.1 (A), A549 (B) and HEp-2 (C) cells were infected with RSV line 19 and A2 
(moi=1) and treated or not with β-escin (5 µg/ml) and AH (25 µg/ml) during 24 h. 
Luciferase activity was measured in cell extracts, and each value was normalized to β-
galactosidase activity in relative luciferase units (RLUs).  CC: cell control (unstimulated 
cells). Data represent mean ± SD for n = 3 independent experiments, performed in 
duplicate. * Significantly different from RSV infected cells (p-value <0.05). 
 
Figure 3. Effect of β-escin and AH on and cytokine production in RSV infected cells. 
J774A.1 (A), A549 (B) and HEp-2 (C) cells were infected with RSV line 19 and A2 (moi=1) 
and treated or not with β-escin (5 µg/ml) and AH (25 µg/ml) during 24 h. IL-6, IL-8 and 
TNF-α was determined by ELISA. CC: cell control (unstimulated cells). Data represent 
mean ± SD for n = 3 independent experiments, performed in triplicate * Significantly 














Figure 4. In vivo evaluation of β-escin and AH antiviral effect. Female Balb/c mice 
were infected with RSV line 19 and A2 (5 × 106 PFU) by intranasal instillation, concomitant 
with 10 mg/kg of AH or 1 mg/kg of β-escin by i.p. injection on day 0. On days 1–4, all mice 
received further inoculations of β-escin or AH i.p. (A-B) Weight was monitored and 
assessed as a percentage of starting weight.  Day 0 refers to time right before inoculation. 
* at day 2, values for AH-treated infected mice were significantly higher than infected mice 
(p-value <0.05). (C) The animals were killed on day 4 and the lungs were used for titration 
of infectious virus. Data show mean ± SD from n = 6 mice/condition. *Significantly different 
from RSV infected mice (p-value <0.05).  
 
Figure 5. Cytokines gene expression determined by real-time PCR. Pulmonary 
cytokines expression was assessed on day 8 p.i. and the data were analyzed using the 
2−∆∆Ct formula. Actin was used as an internal for determination of gene expression. Data 
show mean ± SD from n = 3 mice/condition. *Significantly different from RSV infected mice 
(p-value <0.05).  
 
Figure 6. Lung histology. Light micrographic images of pulmonary histology of H&E-
stained lungs collected at day 8 p.i., shown at original magnification x100, representative 
of n = 3/condition.  
 
Supplementary Figure 1. Dose-dependent response of β-escin and AH on RSV 
replication and inactivation. (A) and (B),  antiviral activity of different concentrations of β-
escin and AH against RSV strains A2 and line 19 in HEp-2 and A549 cells, respectively. 













and line 19. Data represent mean ± SD for n = 3 independent experiments, performed in 
triplicate.  
 
Supplementary Figure 2. Effect of β-escin and AH on NF-κB and AP-1 activation and 
cytokine production in TLRs stimulated epithelial cells. HEp-2 and A549 cells were 
stimulated with Toll Like Receptor (TLR)2/6 (100 ng/ml) and TLR3 (10 µg/ml) ligands and 
treated or not with β-escin (5 µg/ml) and AH (25 µg/ml) for 8 h. (A and B) Luciferase 
activity was measured in cell extracts, and each value was normalized to β-galactosidase 
activity in relative luciferase units (RLUs). (C and D) IL-6 and IL-8 was determined by 
ELISA. CC: cell control (unstimulated cells). Data represent mean ± SD for n = 3 
independent experiments, performed in duplicate.  *Significantly different from TLRs 


























































































Aesculus hippocastanum L. seed extract (AH) and β-escin show virucidal and antiviral 
activities against RSV in vitro 
 
AH and β-escin show NF-κB, AP-1 and cytokine modulating activities in RSV infected 
epithelial and macrophage cell lines 
 
AH, but not β-escin, decreases weight loss and reduces lung titers and inflammation in a 
murine model of RSV infection. 
 
